Madrigal Pharmaceuticals
MDGL
352 hedge funds and large institutions have $10.7B invested in Madrigal Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 107 increasing their positions, 107 reducing their positions, and 37 closing their positions.
135% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 37
50% more capital invested
Capital invested by funds: $7.13B → $10.7B (+$3.6B)
27% more call options, than puts
Call options by funds: $326M | Put options by funds: $258M
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
15% more funds holding
Funds holding: 305 → 352 (+47)
0% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 107
0.74% less ownership
Funds ownership: 106.08% → 105.34% (-0.74%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$148M |
| 2 |
Goldman Sachs
New York
|
+$73.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$61.8M |
| 4 |
BlackRock
New York
|
+$45.1M |
| 5 |
Alkeon Capital Management
New York
|
+$44.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$130M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$108M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$107M |
| 4 |
PC
Paulson & Co
New York
|
-$67.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$59.3M |
MDGL Hedge Fund Activity: Q3 2025 in Review
352 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2025, worth a combined $10.7B — up 50% from $7.13B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new MDGL positions and 37 closed out — a net gain of 50 holders — while 107 added to existing stakes and 107 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $148M. The largest seller was Janus Henderson Group, cutting an estimated $130M.
- 352 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2025, up from 305 in Q2 2025.
- Funds reported $10.7B of Madrigal Pharmaceuticals stock for Q3 2025, up 50% quarter-over-quarter.
- 87 funds opened new Madrigal Pharmaceuticals positions in Q3 2025 and 37 closed out, a net change of +50 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $148M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2025 was Janus Henderson Group, an estimated $130M sold.
Based on aggregated 13F filings for Q3 2025.